BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21211325)

  • 1. [Susceptibility-weighted imaging in detecting brain iron accumulation of Parkinson's disease].
    Huang XM; Sun B; Xue YJ; Duan Q
    Zhonghua Yi Xue Za Zhi; 2010 Nov; 90(43):3054-8. PubMed ID: 21211325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance relaxometry in Parkinson's disease.
    Mondino F; Filippi P; Magliola U; Duca S
    Neurol Sci; 2002 Sep; 23 Suppl 2():S87-8. PubMed ID: 12548357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterizing iron deposition in Parkinson's disease using susceptibility-weighted imaging: an in vivo MR study.
    Zhang J; Zhang Y; Wang J; Cai P; Luo C; Qian Z; Dai Y; Feng H
    Brain Res; 2010 May; 1330():124-30. PubMed ID: 20303339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.
    Jin L; Wang J; Zhao L; Jin H; Fei G; Zhang Y; Zeng M; Zhong C
    Brain; 2011 Jan; 134(Pt 1):50-8. PubMed ID: 21109502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores.
    Atasoy HT; Nuyan O; Tunc T; Yorubulut M; Unal AE; Inan LE
    Neurol India; 2004 Sep; 52(3):332-7. PubMed ID: 15472421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts.
    Michaeli S; Oz G; Sorce DJ; Garwood M; Ugurbil K; Majestic S; Tuite P
    Mov Disord; 2007 Feb; 22(3):334-40. PubMed ID: 17149719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging brain iron and diffusion patterns: a follow-up study of Parkinson's disease in the initial stages.
    Rossi ME; Ruottinen H; Saunamäki T; Elovaara I; Dastidar P
    Acad Radiol; 2014 Jan; 21(1):64-71. PubMed ID: 24331266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishing a baseline phase behavior in magnetic resonance imaging to determine normal vs. abnormal iron content in the brain.
    Haacke EM; Ayaz M; Khan A; Manova ES; Krishnamurthy B; Gollapalli L; Ciulla C; Kim I; Petersen F; Kirsch W
    J Magn Reson Imaging; 2007 Aug; 26(2):256-64. PubMed ID: 17654738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status.
    Martin WR; Wieler M; Gee M
    Neurology; 2008 Apr; 70(16 Pt 2):1411-7. PubMed ID: 18172063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature.
    Péran P; Cherubini A; Assogna F; Piras F; Quattrocchi C; Peppe A; Celsis P; Rascol O; Démonet JF; Stefani A; Pierantozzi M; Pontieri FE; Caltagirone C; Spalletta G; Sabatini U
    Brain; 2010 Nov; 133(11):3423-33. PubMed ID: 20736190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential role of high-field MRI for studies in Parkinson's disease.
    Schuff N
    Mov Disord; 2009; 24 Suppl 2():S684-90. PubMed ID: 19877239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantifying brain iron deposition in patients with Parkinson's disease using quantitative susceptibility mapping, R2 and R2.
    Barbosa JH; Santos AC; Tumas V; Liu M; Zheng W; Haacke EM; Salmon CE
    Magn Reson Imaging; 2015 Jun; 33(5):559-65. PubMed ID: 25721997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson's disease.
    Rizzo G; Martinelli P; Manners D; Scaglione C; Tonon C; Cortelli P; Malucelli E; Capellari S; Testa C; Parchi P; Montagna P; Barbiroli B; Lodi R
    Brain; 2008 Oct; 131(Pt 10):2690-700. PubMed ID: 18819991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minor depression and brain perfusion images in Parkinson's disease.
    Matsui H; Nishinaka K; Oda M; Komatsu K; Kubori T; Udaka F
    Mov Disord; 2006 Aug; 21(8):1169-74. PubMed ID: 16685687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Magnetic resonance imaging in Parkinson's disease--the evaluation of the width of pars compacta on T2 weighted image].
    Moriwaka F; Tashiro K; Itoh K; Hamada T; Miyasaka K
    Rinsho Shinkeigaku; 1992 Jan; 32(1):8-12. PubMed ID: 1628441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI assessment of basal ganglia iron deposition in Parkinson's disease.
    Wallis LI; Paley MN; Graham JM; Grünewald RA; Wignall EL; Joy HM; Griffiths PD
    J Magn Reson Imaging; 2008 Nov; 28(5):1061-7. PubMed ID: 18972346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic cerebrospinal venous insufficiency and iron deposition on susceptibility-weighted imaging in patients with multiple sclerosis: a pilot case-control study.
    Zivadinov R; Schirda C; Dwyer MG; Haacke ME; Weinstock-Guttman B; Menegatti E; Heininen-Brown M; Magnano C; Malagoni AM; Wack DS; Hojnacki D; Kennedy C; Carl E; Bergsland N; Hussein S; Poloni G; Bartolomei I; Salvi F; Zamboni P
    Int Angiol; 2010 Apr; 29(2):158-75. PubMed ID: 20351672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic resonance imaging in parkinsonism.
    Olanow CW
    Neurol Clin; 1992 May; 10(2):405-20. PubMed ID: 1584182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls.
    Burton EJ; McKeith IG; Burn DJ; Williams ED; O'Brien JT
    Brain; 2004 Apr; 127(Pt 4):791-800. PubMed ID: 14749292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic resonance imaging and spectroscopy in Parkinson's disease.
    Martin WR
    Adv Neurol; 2001; 86():197-203. PubMed ID: 11553978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.